Pronota Shows Proof of Concept for Next-Gen Sequencing-Based Protein Biomarker Discovery Platform | GenomeWeb

By Adam Bonislawski

Belgian protein biomarker firm Pronota announced recently that it has successfully completed a proof of concept study for a diagnostic platform employing next-generation sequencing in the identification and quantification of proteins.

The study combined the use of aptamers — short, selectively binding oligonucleotide sequences — with NGS technology, binding the aptamers to target proteins and then sequencing the protein-bound aptamers to quantify the proteins.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.